Gilead builds case for filgotinib in active psoriatic arthritis

Gilead Sciences and Galapagos have presented long-term midphase data on filgotinib in patients with active psoriatic arthritis. The analysis shows responses seen at 16 weeks were sustained out to 52 weeks after the initiation of treatment.